Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07583810CT.gov Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · MALT Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nemtabrutinib (this asset) | City of Hope Medical Center | P2 | CCC · 53 |
| Cyclophosphamide | SWOG Cancer Research Network | P2 | BBB |
| Dexasone | Izidore Lossos, MD | P2 | BBB |
| Rituximab | City of Hope Medical Center | P3 | BBB |
| Etoposide | Fred Hutchinson Cancer Center | P2 | BB |
| Vincristine Sulfate | SWOG Cancer Research Network | P2 | BB |
| Fludarabine | UNC Lineberger Comprehensive Cancer Center | P2 | BB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Obinutuzumab | University of Washington | P2 | BB |
+42 more in the MALT Lymphoma cohort
Other indications for Nemtabrutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 64 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | B · 60 |
| Waldenstrom Macroglobulinemia | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nemtabrutinib in MALT Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nemtabrutinib-malt-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →